Comment
Author: Admin | 2025-04-28
HomeFam-trastuzumab deruxtecan Pronunciation: tras-TOOZ-ue-mab-DER-ux-TEE-kanGeneric name: fam-trastuzumab deruxtecanBrand name: EnhertuDosage form: intravenous powder for injectionDrug class: HER2 inhibitors UsesSide effectsWarningsBefore takingDosageInteractionsFAQ What is Trastuzumab deruxtecan?Trastuzumab deruxtecan (Enhertu) is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors with HER2 gene mutations in certain patients. Trastuzumab deruxtecan may help people with cancer live longer and delay the progression of their disease. The active ingredient, fam trastuzumab deruxtecan nxki, is commonly shortened to trastuzumab deruxtecan or T-DXd.Trastuzumab deruxtecan combines targeted therapy and chemotherapy into one treatment, known as an antibody-drug conjugate (ADC). The targeted therapy part, fam-trastuzumab (T), recognizes and attaches to HER2-positive cancer cells to help block their ability to grow and multiply. Once attached, the chemotherapy component, deruxtecan (DXd), is released inside the cancer cells, destroying them.Trastuzumab deruxtecan mechanism of action is a HER2-directed antibody-drug conjugate. Trastuzumab deruxtecan FDA approval for breast cancer was granted on December 20, 2019, for specific types of breast cancer, and since then the FDA approval extended to cover other conditions. Trastuzumab deruxtecan is approved under the brand name Enhertu by Daiichi Sankyo, Inc.,What is Trastuzumab deruxtecan used for?HER2-Positive Breast CancerUnresectable or Metastatic HER2-Positive Breast Cancer: For adults whose cancer cannot be surgically removed or has spread to other parts of the body, and who have received prior anti-HER2-based treatments in the metastatic setting, or in the neoadjuvant or adjuvant setting with disease recurrence during or within six months of completing therapy.HER2-Low Breast CancerUnresectable or Metastatic HER2-Low Breast Cancer: For adults with HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer that cannot be surgically removed or has metastasized, and who have received prior chemotherapy in the metastatic setting or experienced disease recurrence during or within six months of completing adjuvant chemotherapy.Unresectable or Metastatic HER2-low and HER2-Ultralow and hormone receptor (HR)-positive.
Add Comment